Fenretinide (4-HPR) in chemoprevention of oral leukoplakia

F. Chiesa, N. Tradati, M. Marazza, N. Rossi, P. Boracchi, L. Mariani, F. Formelli, R. Giardini, A. Costa, G. De Palo, U. Veronesi

Research output: Contribution to journalArticle

Abstract

A controlled clinical trial has been underway at the Istituto Nazionale Tumori (INT) of Milan since 1988. The goal of the trial is to evaluate the effectiveness of fenretinide (4-HPR) in preventing relapses, new localizations, and carcinomas in patients with benign postoperative diagnoses who have been surgically treated for oral leukoplakias. This paper presents the design and the preliminary results of this study. To date, 137 patients have been randomized, following surgical excision of oral leukoplakia, to receive either 200 mg 4-HPR daily for 52 weeks or no intervention. Twenty local relapses or new localizations have occurred so far in the control group and 9 in the 4-HPR group. Seven patients have interrupted the intervention because of toxicity. No impaired dark adaptation has been observed. We conclude that 4-HPR is well-tolerated and appears to be effective in preventing relapses and new localizations during the treatment period.

Original languageEnglish
Pages (from-to)255-261
Number of pages7
JournalJournal of Cellular Biochemistry
Volume52
Issue numberSUPPL. 17 F
Publication statusPublished - 1993

Fingerprint

Fenretinide
Oral Leukoplakia
Chemoprevention
Recurrence
Dark Adaptation
Controlled Clinical Trials
Toxicity
Carcinoma
Control Groups

Keywords

  • chemoprevention
  • clinical trials
  • fenretinide
  • oral leukoplakias

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Medicine(all)

Cite this

Chiesa, F., Tradati, N., Marazza, M., Rossi, N., Boracchi, P., Mariani, L., ... Veronesi, U. (1993). Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. Journal of Cellular Biochemistry, 52(SUPPL. 17 F), 255-261.

Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. / Chiesa, F.; Tradati, N.; Marazza, M.; Rossi, N.; Boracchi, P.; Mariani, L.; Formelli, F.; Giardini, R.; Costa, A.; De Palo, G.; Veronesi, U.

In: Journal of Cellular Biochemistry, Vol. 52, No. SUPPL. 17 F, 1993, p. 255-261.

Research output: Contribution to journalArticle

Chiesa, F, Tradati, N, Marazza, M, Rossi, N, Boracchi, P, Mariani, L, Formelli, F, Giardini, R, Costa, A, De Palo, G & Veronesi, U 1993, 'Fenretinide (4-HPR) in chemoprevention of oral leukoplakia', Journal of Cellular Biochemistry, vol. 52, no. SUPPL. 17 F, pp. 255-261.
Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. Journal of Cellular Biochemistry. 1993;52(SUPPL. 17 F):255-261.
Chiesa, F. ; Tradati, N. ; Marazza, M. ; Rossi, N. ; Boracchi, P. ; Mariani, L. ; Formelli, F. ; Giardini, R. ; Costa, A. ; De Palo, G. ; Veronesi, U. / Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. In: Journal of Cellular Biochemistry. 1993 ; Vol. 52, No. SUPPL. 17 F. pp. 255-261.
@article{a6018ffe2ed242a481bcb18bb747b2b8,
title = "Fenretinide (4-HPR) in chemoprevention of oral leukoplakia",
abstract = "A controlled clinical trial has been underway at the Istituto Nazionale Tumori (INT) of Milan since 1988. The goal of the trial is to evaluate the effectiveness of fenretinide (4-HPR) in preventing relapses, new localizations, and carcinomas in patients with benign postoperative diagnoses who have been surgically treated for oral leukoplakias. This paper presents the design and the preliminary results of this study. To date, 137 patients have been randomized, following surgical excision of oral leukoplakia, to receive either 200 mg 4-HPR daily for 52 weeks or no intervention. Twenty local relapses or new localizations have occurred so far in the control group and 9 in the 4-HPR group. Seven patients have interrupted the intervention because of toxicity. No impaired dark adaptation has been observed. We conclude that 4-HPR is well-tolerated and appears to be effective in preventing relapses and new localizations during the treatment period.",
keywords = "chemoprevention, clinical trials, fenretinide, oral leukoplakias",
author = "F. Chiesa and N. Tradati and M. Marazza and N. Rossi and P. Boracchi and L. Mariani and F. Formelli and R. Giardini and A. Costa and {De Palo}, G. and U. Veronesi",
year = "1993",
language = "English",
volume = "52",
pages = "255--261",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "SUPPL. 17 F",

}

TY - JOUR

T1 - Fenretinide (4-HPR) in chemoprevention of oral leukoplakia

AU - Chiesa, F.

AU - Tradati, N.

AU - Marazza, M.

AU - Rossi, N.

AU - Boracchi, P.

AU - Mariani, L.

AU - Formelli, F.

AU - Giardini, R.

AU - Costa, A.

AU - De Palo, G.

AU - Veronesi, U.

PY - 1993

Y1 - 1993

N2 - A controlled clinical trial has been underway at the Istituto Nazionale Tumori (INT) of Milan since 1988. The goal of the trial is to evaluate the effectiveness of fenretinide (4-HPR) in preventing relapses, new localizations, and carcinomas in patients with benign postoperative diagnoses who have been surgically treated for oral leukoplakias. This paper presents the design and the preliminary results of this study. To date, 137 patients have been randomized, following surgical excision of oral leukoplakia, to receive either 200 mg 4-HPR daily for 52 weeks or no intervention. Twenty local relapses or new localizations have occurred so far in the control group and 9 in the 4-HPR group. Seven patients have interrupted the intervention because of toxicity. No impaired dark adaptation has been observed. We conclude that 4-HPR is well-tolerated and appears to be effective in preventing relapses and new localizations during the treatment period.

AB - A controlled clinical trial has been underway at the Istituto Nazionale Tumori (INT) of Milan since 1988. The goal of the trial is to evaluate the effectiveness of fenretinide (4-HPR) in preventing relapses, new localizations, and carcinomas in patients with benign postoperative diagnoses who have been surgically treated for oral leukoplakias. This paper presents the design and the preliminary results of this study. To date, 137 patients have been randomized, following surgical excision of oral leukoplakia, to receive either 200 mg 4-HPR daily for 52 weeks or no intervention. Twenty local relapses or new localizations have occurred so far in the control group and 9 in the 4-HPR group. Seven patients have interrupted the intervention because of toxicity. No impaired dark adaptation has been observed. We conclude that 4-HPR is well-tolerated and appears to be effective in preventing relapses and new localizations during the treatment period.

KW - chemoprevention

KW - clinical trials

KW - fenretinide

KW - oral leukoplakias

UR - http://www.scopus.com/inward/record.url?scp=0027224034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027224034&partnerID=8YFLogxK

M3 - Article

C2 - 8412202

AN - SCOPUS:0027224034

VL - 52

SP - 255

EP - 261

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - SUPPL. 17 F

ER -